Aptamer Group Plc (GB:APTA)
LSE:APTA
Top Page
Aptamer Group Plc
(LSE:APTA)
Select Model
Select Model
Rating:40Underperform
Price Target:
0.62 p
▼(-22.75% Downside)
Action:DowngradedDate:03/25/26
The score is primarily held down by very weak financial performance (sharp revenue collapse, continued losses, and negative cash flows). Technical indicators also remain bearish with the stock below major moving averages and negative MACD; oversold momentum readings provide only limited support. Valuation is constrained by a negative P/E and no dividend data.
Positive Factors
Improved leverage
Improved debt-to-equity indicates the company has reduced leverage pressure, increasing financial flexibility. Over 2-6 months this can lower refinancing risk, reduce interest burden, and buy time for R&D and commercialization efforts without immediate insolvency pressure.
Negative Factors
Severe revenue decline
A near-total revenue collapse is a structural red flag: it erodes scale, damages customer relationships, and reduces market credibility. Over the medium term this undermines the firm's ability to fund R&D, retain staff, and execute commercialization strategies without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
Improved debt-to-equity indicates the company has reduced leverage pressure, increasing financial flexibility. Over 2-6 months this can lower refinancing risk, reduce interest burden, and buy time for R&D and commercialization efforts without immediate insolvency pressure.
Read all positive factors
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£17.56M
Dividend YieldN/A
Average Volume (3M)15.29M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth39.88%
EPS Growth81.33%
CountryUK
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,927,061,800
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aptamer Group Plc Business Overview & Revenue Model
Company Description
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom and internationally. The company's binders engineered to address issues which founds with molecules, such as antibodies; and offers solutions to b...
How the Company Makes Money
null...
Aptamer Group Plc Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38M | 1.20M | 860.00K | 1.75M | 4.04M | 1.28M |
| Gross Profit | 438.00K | 350.00K | 250.00K | 359.00K | 2.69M | 538.40K |
| EBITDA | -2.39M | -2.28M | -2.81M | -7.36M | -2.19M | -2.24M |
| Net Income | -2.46M | -2.42M | -2.96M | -7.84M | -2.09M | -1.85M |
Balance Sheet | ||||||
| Total Assets | 3.73M | 2.83M | 2.77M | 2.75M | 11.52M | 2.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.53M | 1.06M | 870.00K | 234.00K | 6.69M | 369.00K |
| Total Debt | 333.00K | 491.00K | 817.00K | 1.08M | 1.31M | 78.00K |
| Total Liabilities | 1.48M | 1.45M | 1.88M | 2.45M | 3.47M | 1.96M |
| Stockholders Equity | 2.25M | 1.38M | 887.00K | 304.00K | 8.05M | 105.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.93M | -2.01M | -2.41M | -6.09M | -2.79M | -1.26M |
| Operating Cash Flow | -1.91M | -2.00M | -2.28M | -4.06M | -2.38M | -1.10M |
| Investing Cash Flow | -102.00K | -92.00K | -122.00K | -2.03M | -418.00K | -339.20K |
| Financing Cash Flow | 1.57M | 2.28M | 3.04M | -365.00K | 9.12M | 1.50M |
Aptamer Group Plc Technical Analysis
Negative
0.80
Price Trends
0.82
Negative
0.86
Negative
0.79
Negative
Market Momentum
-0.07
Positive
25.37
Positive
33.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.82, and above the 200-day MA of 0.79, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 25.37 is Positive, neither overbought nor oversold. The STOCH value of 33.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.
Aptamer Group Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £97.97M | ― | 65.83% | 8.33% | -3.61% | -6.35% | |
56 Neutral | £24.35M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £17.82M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
42 Neutral | £298.31M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £17.56M | -6.19 | -213.66% | ― | 39.88% | 81.33% | |
40 Underperform | £8.58M | -0.25 | -316.67% | ― | 72.17% | 79.03% |
* Healthcare Sector Average
GB:APTA
Aptamer Group Plc
0.63
0.37
140.38%
GB:AVCT
Avacta Group plc
71.00
33.00
86.84%
GB:BVXP
Bioventix
1,800.00
-472.77
-20.80%
GB:OBD
Oxford BioDynamics
0.19
-0.26
-57.78%
GB:FAB
Fusion Antibodies Plc
14.25
7.70
117.56%
GB:AREC
Arecor Therapeutics PLC
64.50
26.50
69.74%
Aptamer Group Plc Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Aptamer Group Raises £4.5m in Funding Round Ahead of Key Shareholder Vote
Positive
Mar 31, 2026
Aptamer Group plc has completed a retail offer that raised approximately £274,000 before expenses through the planned issue of 45,665,573 new shares at 0.6p each, contingent on shareholder approval at a general meeting scheduled for 13 April ...
Private Placements and Financing
Aptamer Group opens £0.5m retail offer alongside £4.3m placing
Positive
Mar 26, 2026
Aptamer Group has launched a retail share offer via the BookBuild platform to raise up to £0.5 million by issuing as many as 83,333,333 new shares at 0.6 pence each to existing UK shareholders, with one transferable warrant granted for every ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Aptamer Group Raises £4.3m to Accelerate AI and Radiopharmaceutical Growth Plans
Positive
Mar 26, 2026
Aptamer Group has raised £4.275m through a placing and subscription of new shares at 0.6p each, receiving strong backing from existing and new investors and participation from its directors. The fundraising is complemented by a separate retai...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aptamer Group lifts revenues and extends cash runway as Optimer deals scale up
Positive
Mar 25, 2026
Aptamer Group reported interim revenue of £0.83 million for the six months to 31 December 2025, a 27% rise year on year, while narrowing its adjusted EBITDA loss to £1.0 million and ending the period with £1.5 million in cash, suppo...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Aptamer Group launches £3.75m equity raise to fund AI-enabled discovery and pipeline expansion
Positive
Mar 25, 2026
Aptamer Group plc has launched an equity fundraising of at least £3.75 million through a placing and direct subscription of new shares at 0.6 pence, alongside a retail offer of up to £0.5 million for existing shareholders at the same pri...
Business Operations and StrategyProduct-Related Announcements
Aptamer Group launches Optimer radiopharmaceutical push with Radiopharmium
Positive
Mar 18, 2026
Aptamer Group has launched a targeted radiopharmaceutical development programme in collaboration with Radiopharmium Ltd, aiming to build a proprietary pipeline of Optimer®-based radioconjugates against three high‑value therapeutic targe...
Business Operations and StrategyRegulatory Filings and Compliance
Aptamer Group Updates Status of EMI Share Option Block Listing
Neutral
Mar 10, 2026
Aptamer Group plc has provided an interim review of its block listing related to The Aptamer Group EMI Share Option Scheme, covering the period from 26 August 2025 to 24 February 2026. Over this timeframe, no new options were exercised, 6,000 opti...
Business Operations and StrategyProduct-Related Announcements
Aptamer Group hits key milestone in Metir pathogen detector collaboration
Positive
Feb 17, 2026
Aptamer Group plc has completed Phase 1 of its collaboration with Metir plc, achieving the technical feasibility milestone for developing Optimer® binders to detect Cryptosporidium parvum oocysts in water using Metir’s real-time, contin...
Business Operations and StrategyProduct-Related Announcements
Aptamer’s Optimer Tech Powers Twist Bioscience’s New TrueAmp NGS Library Prep Kit
Positive
Feb 11, 2026
Twist Bioscience has launched its new TrueAmp Library Preparation Kit for next-generation sequencing workflows, incorporating Aptamer Group’s proprietary Optimer binders to enable room-temperature stability and enhanced performance. The kit ...
Business Operations and StrategyFinancial Disclosures
Aptamer Group Secures New Pharma Contracts and First Cash from Optimer Licensing
Positive
Jan 29, 2026
Aptamer Group has reported £190,000 of new fee-for-service contracts and extensions, largely driven by repeat Optimer® development work with top‑tier global pharmaceutical companies, lifting its FY26 fee-for-service order book to m...
Business Operations and StrategyFinancial Disclosures
Aptamer Group Reasserts Cash Runway to June 2027 Amid Media Speculation
Positive
Jan 7, 2026
Aptamer Group plc issued a brief trading update to address media comment and speculation following an earlier announcement, reiterating that its current cash resources provide funding headroom through to June 2027. The confirmation of this cash ru...
Business Operations and StrategyFinancial Disclosures
Aptamer Group lifts H1 revenue 27% as licensing push builds recurring income
Positive
Jan 7, 2026
Aptamer Group reported a 27% year-on-year rise in unaudited first-half revenue to £0.83 million, backed by a fee-for-service order book of more than £2.0 million for FY26 and a £3.1 million sales pipeline, giving the board confidenc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.